AVATACE-1: Bevacizumab (Avastin) as Inhibitor of Collateral Tumor Vessel Growth During Transarterial Chemoembolisation (TACE) for Hepatocellular Carcinoma (HCC) a Pilot Trial.

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 03 Nov 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bevacizumab (Primary) ; Doxorubicin; Ethiodized oil
Indications Liver cancer
Focus Therapeutic Use
Acronyms AVATACE; AVATACE-1

Most Recent Events

01 Nov 2010 Primary endpoint 'Progression-free-survival-rate' has not been met, accoridng to data presented at AASLD.
01 Nov 2010 Results were presented at the 61st Annual Meeting of the Association for the Study of Liver Diseases.
27 Apr 2010 Actual patient number (32) added as reported by ClinicalTrials.gov.

Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

IP authentication when working within your organization’s network.
Login with username/password or try access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days.
Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Contact your organization’s admin about adding this content to your AdisInsight subscription
Buy a PDF version of the profile.
Request a free trial

Welcome to AdisInsight